0000899243-22-037521.txt : 20221202
0000899243-22-037521.hdr.sgml : 20221202
20221202192140
ACCESSION NUMBER: 0000899243-22-037521
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221202
FILED AS OF DATE: 20221202
DATE AS OF CHANGE: 20221202
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sorrento Therapeutics, Inc.
CENTRAL INDEX KEY: 0000850261
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39852
FILM NUMBER: 221443418
BUSINESS ADDRESS:
STREET 1: 4955 DIRECTORS PLACE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-203-4100
MAIL ADDRESS:
STREET 1: 4955 DIRECTORS PLACE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER NAME:
FORMER CONFORMED NAME: QUIKBYTE SOFTWARE INC
DATE OF NAME CHANGE: 19920703
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Scilex Holding Co
CENTRAL INDEX KEY: 0001820190
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 960 SAN ANTONIO ROAD
CITY: PALO ALTO
STATE: CA
ZIP: 94303
BUSINESS PHONE: (650) 516-4310
MAIL ADDRESS:
STREET 1: 960 SAN ANTONIO ROAD
CITY: PALO ALTO
STATE: CA
ZIP: 94303
FORMER COMPANY:
FORMER CONFORMED NAME: Scilex Holding Company/DE
DATE OF NAME CHANGE: 20221117
FORMER COMPANY:
FORMER CONFORMED NAME: Vickers Vantage Corp. I
DATE OF NAME CHANGE: 20200804
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-12-02
0
0001820190
Scilex Holding Co
SCLX
0000850261
Sorrento Therapeutics, Inc.
4955 DIRECTORS PLACE
SAN DIEGO
CA
94303
0
0
1
0
Warrants to Purchase Common Stock
11.50
2022-12-02
4
P
0
224841
0.3507
A
2022-11-10
2027-11-10
Common Stock
224841
4490617
D
The price reported in Column 8 is a weighted average price. These warrants were purchased in multiple transactions at prices ranging from $0.32 to $0.36 per warrant, inclusive. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or a securityholder of the Issuer, full information regarding the number of warrants purchased at each separate price.
/s/ Henry Ji, Ph.D., President, Chief Executive Officer and Chairman of the Board, Sorrento Therapeutics, Inc.
2022-12-02